Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr 26;15(4):142-153.
doi: 10.4330/wjc.v15.i4.142.

Optimization of the pharmacological therapy in patients with poly-vascular disease: A multidisciplinary approach

Rocco Gioscia  1 , Claudio Castagno  2 , Monica Verdoia  1 , Barbara Conti  2 , Enzo Forliti  2 , Andrea Rognoni  3
Affiliations
Review

Optimization of the pharmacological therapy in patients with poly-vascular disease: A multidisciplinary approach

Rocco Gioscia et al. World J Cardiol. .

Abstract

The recent shift of the concept of cardiovascular disease as a chronic progressive condition, potentially involving multiple districts, has driven attention to the optimal management of patients with concomitant coronary and peripheral artery disease, representing a subset of patients with an increased risk of events and impaired survival. Recent pharmacological achievements in terms of antithrombotic therapy and lipid-lowering drugs allow multiple therapeutical combinations, thus requiring optimizing the treatment in a tailored fashion according to patients' risk profiles. Nevertheless, data dedicated to this specific subset of patients are still modest. We summarize currently available strategies and indications for the management of antithrombotic and lipid-lowering drugs in patients with the poly-vascular disease.

Keywords: Antitrombotic therapy; Atherosclerosis; Cholesterol; Coronary artery disease; PCSK9; Poly-vascular disease; Statins.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: All the authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
Flow-chart for the management of antithrombotic therapy in patients with coronary artery disease. CAD: Coronary artery disease; DAPT: Dual antiplatelet therapy; DM: Disease management; eGRF: Glomerular Filtration Rate; PAD: Peripheral arterial disease; MI: Myocardial infarction.
Figure 2
Figure 2
Antithrombotic strategies in patients with peripheral artery disease according to vascular guidelines. PAD: Peripheral artery disease; CVD: Cardiovascular disease; CAD: Coronary artery disease.
Figure 3
Figure 3
Current indications to lipid-lowering drugs in patients with coronary and peripheral artery disease. CVD: Cardiovascular disease; LDL-C: Low-density Lipoprotein Cholesterol; PCSK9: Proprotein convertase subtilisinkexin type 9; siRNA: Small interfering RNA.
See this image and copyright information in PMC

References

    1. Bauersachs R, Zeymer U, Brière JB, Marre C, Bowrin K, Huelsebeck M. Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review. Cardiovasc Ther. 2019;2019:8295054. - PMC - PubMed
    1. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407–477. - PubMed
    1. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, Popma JJ, Stevenson W. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease) Circulation. 2006;114:2850–2870. - PubMed
    1. Chrysant SG. Stopping the cardiovascular disease continuum: Focus on prevention. World J Cardiol. 2010;2:43–49. - PMC - PubMed
    1. Kubica J, Adamski P, Niezgoda P, Alexopoulos D, Badarienė J, Budaj A, Buszko K, Dudek D, Fabiszak T, Gąsior M, Gil R, Gorog DA, Grajek S, Gurbel PA, Gruchała M, Jaguszewski MJ, James S, Jeong YH, Jilma B, Kasprzak JD, Kleinrok A, Kubica A, Kuliczkowski W, Legutko J, Lesiak M, Siller-Matula JM, Nadolny K, Pstrągowski K, Di Somma S, Specchia G, Stępińska J, Tantry US, Tycińska A, Verdoia M, Wojakowski W, Navarese EP. Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. Cardiol J. 2020;27:661–676. - PMC - PubMed